Drug:
Reaction: DISEASE PROGRESSION
20250101 - 20251231
No. 601 - 700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 601 | 25031019 |
CL |
1 | |
Disease progression, |
||||
POLATUZUMAB VEDOTIN, |
||||
| 602 | 25031511 |
FR |
70 | 1 |
Enterocolitis, Mucosal inflammation, Disease progression, Drug ineffective, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, FLUDARABINE PHOSPHATE, AZACITIDINE, AZACITIDINE FOR, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYCLOSPORINE, TREOSULFAN, ACYCLOVIR, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, |
||||
| 603 | 25031637 |
US |
55 | 2 |
Drug ineffective, Disease progression, |
||||
FLUOROURACIL, OXALIPLATIN, |
||||
| 604 | 25032242 |
AT |
||
Pneumococcal sepsis, Pneumonia, Diffuse large B-cell lymphoma, Disease progression, Graft versus host disease, Gastroenteritis astroviral, Dry eye, Oral herpes, Weight decreased, Dysphagia, Hepatic enzyme increased, Dyspnoea, |
||||
DOLUTEGRAVIR SODIUM, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, METHOTREXATE, METHOTREXATE SODIUM, CYTARABINE, CISPLATIN, PREDNISONE, POLATUZUMAB VEDOTIN, BENDAMUSTINE HCL, METHYLPREDNISOLONE, METHYLPREDNISOLONE, BETAMETHASONE DIPROPIONATE, BUDESONIDE, |
||||
| 605 | 25032243 |
AT |
||
Pneumococcal sepsis, Pneumonia, Diffuse large B-cell lymphoma, Disease progression, Graft versus host disease, Gastroenteritis astroviral, Dry eye, Oral herpes, Weight decreased, Dysphagia, Hepatic enzyme increased, Dyspnoea, |
||||
DOLUTEGRAVIR SODIUM, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, METHOTREXATE, METHOTREXATE SODIUM, CYTARABINE, CISPLATIN, PREDNISONE, POLATUZUMAB VEDOTIN, BENDAMUSTINE HCL, METHYLPREDNISOLONE, METHYLPREDNISOLONE, BETAMETHASONE DIPROPIONATE, BUDESONIDE, |
||||
| 606 | 25032311 |
DK |
53 | 1 |
COVID-19, Pyrexia, Sepsis, Alpha haemolytic streptococcal infection, Disease progression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BORTEZOMIB FOR INJECTION, BORTEZOMIB, DOXORUBICIN, |
||||
| 607 | 25032332 |
FR |
2 | |
Mucosal inflammation, Asthenia, Decreased appetite, Weight decreased, Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 608 | 25032404 |
IN |
69 | 1 |
Drug ineffective, Disease progression, |
||||
TRIPTORELIN, BICALUTAMIDE, |
||||
| 609 | 25033247 |
US |
1 | |
Disease progression, General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 610 | 25033781 |
GB |
2 | |
Disease progression, |
||||
MIRVETUXIMAB SORAVTANSINE, |
||||
| 611 | 25028452 |
EG |
50 | 2 |
Disease progression, Cerebral disorder, Metastases to liver, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, BEVACIZUMAB, CARBOPLATIN, |
||||
| 612 | 25028563 |
GB |
19 | 1 |
Malignant neoplasm progression, Pancreatitis acute, Disease progression, Jaundice cholestatic, Off label use, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, CABOZANTINIB, CABOZANTINIB, PREGABALIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, MORPHINE SULFATE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, FUROSEMIDE, GLYCOPYRROLATE, LANSOPRAZOLE, PREGABALIN, PREGABALIN, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LORAZEPAM, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, MORPHINE SULFATE, |
||||
| 613 | 25028608 |
DE |
87 | |
Urinary retention, Cytokine release syndrome, Diffuse large B-cell lymphoma, Disease progression, |
||||
LENALIDOMIDE, GLOFITAMAB, |
||||
| 614 | 25028846 |
PT |
23 | 1 |
Disease progression, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 615 | 25028907 |
US |
53 | 1 |
Disease progression, |
||||
VANDETANIB, |
||||
| 616 | 25025853 |
IT |
2 | |
Alveolar rhabdomyosarcoma, Disease progression, |
||||
DACTINOMYCIN, DOXORUBICIN, MELPHALAN, CYTARABINE, IFOSFAMIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BUSULFAN, |
||||
| 617 | 25025921 |
JP |
2 | |
Disease progression, |
||||
ATEZOLIZUMAB, PACLITAXEL, |
||||
| 618 | 25025972 |
ZA |
2 | |
Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, PACLITAXEL, PACLITAXEL, |
||||
| 619 | 25026036 |
AT |
||
Metastases to liver, Disease progression, |
||||
RITUXIMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CYTARABINE, CISPLATIN, POLATUZUMAB VEDOTIN, BENDAMUSTINE HCL, TOCILIZUMAB, |
||||
| 620 | 25026344 |
MX |
50 | 2 |
Disease progression, |
||||
BEVACIZUMAB, |
||||
| 621 | 25026363 |
US |
||
Disease progression, |
||||
DURVALUMAB, |
||||
| 622 | 25026426 |
AU |
58 | 1 |
Disease progression, Drug intolerance, Metastases to lung, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, GEMCITABINE HYDROCHLORIDE, |
||||
| 623 | 25026503 |
IN |
58 | 1 |
Disease progression, Drug ineffective, |
||||
CAPECITABINE, |
||||
| 624 | 25026507 |
US |
58 | 2 |
Disease progression, Drug ineffective, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DOCETAXEL, DOCETAXEL ANHYDROUS, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, RAMUCIRUMAB, RAMUCIRUMAB, PACLITAXEL, |
||||
| 625 | 25026578 |
IT |
53 | 2 |
Drug ineffective for unapproved indication, Disease progression, |
||||
ETOPOSIDE, CARBOPLATIN, LORLATINIB, LORLATINIB, |
||||
| 626 | 25026767 |
US |
86 | 1 |
Disease progression, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 627 | 25027223 |
US |
67 | 1 |
Disease progression, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 628 | 25021169 |
ID |
5 | 1 |
Off label use, Off label use, Disease progression, |
||||
BEVACIZUMAB, OXYGEN, 0XYGEN, |
||||
| 629 | 25021346 |
HU |
||
Metastases to central nervous system, Disease progression, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, PACLITAXEL, CARBOPLATIN, |
||||
| 630 | 25021594 |
RS |
2 | |
Disease progression, |
||||
RITUXIMAB, POLATUZUMAB VEDOTIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE, BENDAMUSTINE HCL, |
||||
| 631 | 25021718 |
JP |
2 | |
Disease progression, Pleural effusion, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 632 | 25021829 |
ES |
12 | 2 |
Intestinal haemorrhage, Off label use, Disease progression, |
||||
EMAPALUMAB-LZSG, |
||||
| 633 | 25021972 |
AU |
59 | 2 |
Disease progression, |
||||
ATEZOLIZUMAB, CARBOPLATIN, ETOPOSIDE, |
||||
| 634 | 25022067 |
BD |
45 | 2 |
Disease progression, Drug ineffective, Death, Cardiac disorder, |
||||
RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CYTARABINE, CISPLATIN, LENALIDOMIDE, ACALABRUTINIB, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE, DOXORUBICIN, |
||||
| 635 | 25022437 |
IN |
66 | 2 |
Disease progression, Mouth ulceration, |
||||
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 636 | 25022580 |
US |
||
Disease progression, |
||||
CAPIVASERTIB, |
||||
| 637 | 25022707 |
IN |
70 | 1 |
Drug ineffective, Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, |
||||
| 638 | 25022821 |
IT |
53 | 2 |
Drug ineffective, Neutropenia, Myelosuppression, Hepatotoxicity, Thrombocytopenia, Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, CAPECITABINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CARBOPLATIN, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, BLEOMYCIN, BLEOMYCIN SULFATE, NEBIVOLOL, NEBIVOLOL HYDROCHLORIDE, |
||||
| 639 | 25022852 |
PL |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 640 | 25023138 |
US |
61 | 2 |
Disease progression, Rhabdomyolysis, |
||||
| 641 | 25023145 |
IN |
40 | 2 |
Disease progression, |
||||
CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 642 | 25023172 |
KW |
26 | 2 |
Disease progression, |
||||
CARBOPLATIN, PACLITAXEL, |
||||
| 643 | 25023265 |
AT |
||
Disease progression, Off label use, |
||||
AVAPRITINIB, |
||||
| 644 | 25023390 |
TR |
48 | 2 |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 645 | 25023474 |
US |
4 | |
Drug ineffective, Disease progression, |
||||
FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, OXALIPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, TRASTUZUMAB, PEMBROLIZUMAB, PACLITAXEL, CISPLATIN, |
||||
| 646 | 25023535 |
GB |
1 | 1 |
Therapy non-responder, Disease progression, |
||||
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, |
||||
| 647 | 25023539 |
IN |
70 | 1 |
Drug ineffective, Disease progression, |
||||
DOXORUBICIN, DOXORUBICIN, |
||||
| 648 | 25023541 |
JP |
35 | 2 |
Disease progression, Drug ineffective, |
||||
EPIRUBICIN HYDROCHLORIDE, LEUPROLIDE ACETATE, DENOSUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 649 | 25023546 |
IN |
21 | 1 |
Drug ineffective, Disease progression, |
||||
ETOPOSIDE, ETOPOSIDE, CISPLATIN, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, BLEOMYCIN, BLEOMYCIN SULFATE, BLEOMYCIN, BLEOMYCIN SULFATE, |
||||
| 650 | 25023588 |
GB |
19 | 1 |
Pancreatitis acute, Off label use, Intentional product misuse, Jaundice cholestatic, Disease progression, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, CABOZANTINIB, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, PREGABALIN, |
||||
| 651 | 25023606 |
US |
79 | 1 |
Atrial fibrillation, Hallucination, visual, Disease progression, Hyperhidrosis, Dehydration, Diplopia, Abnormal behaviour, Fall, Confusional state, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, CLONAZEPAM, CARBIDOPA LEVODOPA, RASAGILINE, RASAGILINE MESYLATE, DONEPEZIL HYDROCHLORIDE, DROXIDOPA, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, AZELASTINE, FISH OIL, |
||||
| 652 | 25023697 |
US |
85 | 1 |
Disease progression, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 653 | 25024078 |
ES |
61 | 2 |
Disease progression, Metastases to spine, Diplopia, Headache, Muscular weakness, |
||||
SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREDNISONE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 654 | 25024132 |
EG |
42 | 2 |
Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, |
||||
| 655 | 25024459 |
ES |
1 | |
Atrioventricular block, Disease progression, |
||||
AGALSIDASE BETA, CARBAMAZEPINE, |
||||
| 656 | 25024800 |
CA |
||
Disease progression, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, PALBOCICLIB, |
||||
| 657 | 25024903 |
US |
12 | 1 |
Disease progression, Drug ineffective for unapproved indication, |
||||
TERBINAFINE HYDROCHLORIDE, TERBINAFINE, TERBINAFINE HYDROCHLORIDE, TERBINAFINE, TERBINAFINE HYDROCHLORIDE, TERBINAFINE, VORICONAZOLE, VORICONAZOLE, VORICONAZOLE, |
||||
| 658 | 25025010 |
CA |
63 | 1 |
Disease progression, |
||||
FLUCONAZOLE, |
||||
| 659 | 25025093 |
DE |
87 | |
Cytokine release syndrome, Urinary retention, Diffuse large B-cell lymphoma, Disease progression, |
||||
LENALIDOMIDE, GLOFITAMAB, |
||||
| 660 | 25025249 |
JP |
2 | |
Disease progression, |
||||
ATEZOLIZUMAB, ETOPOSIDE, CARBOPLATIN, |
||||
| 661 | 25025398 |
JP |
10 | 2 |
Disease progression, |
||||
QUIZARTINIB, |
||||
| 662 | 25025516 |
SG |
||
Disease progression, Off label use, |
||||
ZANUBRUTINIB, |
||||
| 663 | 25025578 |
CN |
51 | 2 |
Disease progression, |
||||
BEVACIZUMAB, PACLITAXEL, DOCETAXEL, DOCETAXEL ANHYDROUS, PEMETREXED, PEMETREXED DISODIUM, PEMBROLIZUMAB, |
||||
| 664 | 25025591 |
FR |
||
Disease progression, Off label use, |
||||
RITUXIMAB, GLOFITAMAB, |
||||
| 665 | 25015474 |
DE |
||
Diffuse large B-cell lymphoma, Disease progression, Product use issue, |
||||
RITUXIMAB, POLATUZUMAB VEDOTIN, |
||||
| 666 | 25016059 |
GR |
||
Acute lymphocytic leukaemia, Breast cancer metastatic, Breast cancer recurrent, Disease progression, Malignant neoplasm progression, Second primary malignancy, |
||||
BEVACIZUMAB, EVEROLIMUS, ANASTROZOLE, ANASTROZOLE TABLETS, CAPECITABINE, CARBOPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOCETAXEL, DOCETAXEL ANHYDROUS, EPIRUBICIN HYDROCHLORIDE, EXEMESTANE, FULVESTRANT, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, PACLITAXEL, PACLITAXEL, TAMOXIFEN CITRATE, |
||||
| 667 | 25016132 |
IL |
78 | 1 |
Disease progression, Product use issue, Off label use, |
||||
GILTERITINIB, VENETOCLAX, |
||||
| 668 | 25016178 |
CH |
||
Disease progression, |
||||
TRASTUZUMAB, PERTUZUMAB, PACLITAXEL, |
||||
| 669 | 25016426 |
PL |
37 | 1 |
Disease progression, Drug ineffective for unapproved indication, Gastrointestinal disorder, Off label use, |
||||
PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, METHYLPREDNISOLONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 670 | 25016437 |
IT |
||
Death, Brain sarcoma, Disease progression, Sarcoma, Off label use, |
||||
BEVACIZUMAB, BEVACIZUMAB, BEVACIZUMAB, |
||||
| 671 | 25016563 |
IN |
2 | |
Disease progression, |
||||
IRINOTECAN HYDROCHLORIDE, |
||||
| 672 | 25016964 |
IN |
43 | 1 |
Drug ineffective, Disease progression, White blood cell count decreased, |
||||
POLATUZUMAB VEDOTIN, |
||||
| 673 | 25017099 |
JP |
72 | 1 |
Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 674 | 25017118 |
US |
39 | 2 |
Disease recurrence, Disease progression, Stroke-like migraine attacks after radiation therapy, |
||||
LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, TEMOZOLOMIDE, LOMUSTINE, |
||||
| 675 | 25017152 |
US |
54 | 1 |
Disease progression, |
||||
CARBOPLATIN, ETOPOSIDE, |
||||
| 676 | 25017474 |
US |
2 | |
Breast cancer female, Disease progression, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 677 | 25017716 |
CA |
52 | 1 |
Disease progression, Metastases to central nervous system, Metastases to liver, Pancytopenia, Drug ineffective, Off label use, |
||||
BRIGATINIB, BRIGATINIB, BEVACIZUMAB, CAPECITABINE, CAPECITABINE, CAPECITABINE, CAPECITABINE, CAPECITABINE, CISPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, FAM-TRASTUZUMAB DERUXTECAN-NXKI, ENTRECTINIB, ETHIODIZED OIL, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PEMBROLIZUMAB, PEMBROLIZUMAB, LORLATINIB, LORLATINIB, MITOMYCIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OSIMERTINIB, PACLITAXEL, PACLITAXEL, PACLITAXEL, PEMETREXED, PEMETREXED DISODIUM, PERTUZUMAB, PERTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, CISPLATIN, ETHIODIZED OIL, MITOMYCIN, |
||||
| 678 | 25018158 |
EG |
62 | 2 |
Disease progression, Drug ineffective, |
||||
ATEZOLIZUMAB, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 679 | 25018380 |
GB |
||
Disease progression, |
||||
VENETOCLAX, |
||||
| 680 | 25019292 |
SE |
1 | |
Disease progression, |
||||
RADIUM RA 223 DICHLORIDE, |
||||
| 681 | 25019421 |
US |
84 | 1 |
Drug intolerance, Disease progression, Product prescribing issue, Product use in unapproved indication, |
||||
AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, RIFAMPIN, ETHAMBUTOL HYDROCHLORIDE, AMIKACIN, |
||||
| 682 | 25019510 |
57 | ||
Off label use, Epstein-Barr virus infection, Disease progression, Haemophagocytic lymphohistiocytosis, Therapy partial responder, |
||||
RUXOLITINIB, RUXOLITINIB, |
||||
| 683 | 25019520 |
23 | ||
Off label use, Therapy partial responder, Epstein-Barr virus infection, Disease progression, Haemophagocytic lymphohistiocytosis, |
||||
RUXOLITINIB, RUXOLITINIB, |
||||
| 684 | 25019939 |
US |
2 | |
Disease progression, Inappropriate schedule of product administration, |
||||
TRIFLURIDINE AND TIPIRACIL, |
||||
| 685 | 25019997 |
|||
Amyotrophic lateral sclerosis, Disease progression, Therapy change, |
||||
LORAZEPAM, |
||||
| 686 | 25022933 |
2 | ||
Pulmonary arterial hypertension, Disease progression, |
||||
MACITENTAN, SELEXIPAG, AMBRISENTAN, |
||||
| 687 | 25011088 |
AR |
||
Disease progression, |
||||
RITUXIMAB, ETOPOSIDE, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, IFOSFAMIDE, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, OXALIPLATIN, |
||||
| 688 | 25011093 |
JP |
2 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 689 | 25011120 |
JP |
2 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 690 | 25011131 |
JP |
1 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 691 | 25011398 |
JP |
1 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 692 | 25011495 |
CA |
52 | 1 |
Disease progression, Metastases to central nervous system, Metastases to liver, Off label use, Pancytopenia, Drug ineffective, |
||||
BEVACIZUMAB, CAPECITABINE, CAPECITABINE, PACLITAXEL, PACLITAXEL, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PEMETREXED, PEMETREXED DISODIUM, BRIGATINIB, BRIGATINIB, CISPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, ENTRECTINIB, ETHIODIZED OIL, MITOMYCIN, LORLATINIB, LORLATINIB, OSIMERTINIB, OXALIPLATIN, OXALIPLATIN, PEMBROLIZUMAB, PEMBROLIZUMAB, PERTUZUMAB, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, TRASTUZUMAB, FLUOROURACIL, |
||||
| 693 | 25011596 |
IT |
55 | 1 |
Disease progression, |
||||
| 694 | 25011642 |
US |
65 | 1 |
Insomnia, Disease progression, |
||||
DEUTETRABENAZINE, |
||||
| 695 | 25011792 |
CN |
2 | |
Disease progression, |
||||
GLOFITAMAB, |
||||
| 696 | 25011852 |
ID |
1 | |
Disease progression, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, |
||||
| 697 | 25011897 |
BR |
31 | 2 |
Disease progression, |
||||
GILTERITINIB, |
||||
| 698 | 25011913 |
US |
68 | 1 |
Staphylococcal infection, Bone cancer metastatic, Malignant pleural effusion, Disease progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOXYCYCLINE, DOXYCYCLINE HYCLATE, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, SODIUM FLUORIDE, SODIUM FLUORIDE F 18, SODIUM FLUORIDE F-18, TOOTHPASTE, SODIUM FLUORIDE F18, CLEAR MINT, GEL TOOTHPASTE, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, |
||||
| 699 | 25012037 |
JP |
1 | |
Disease progression, Drug ineffective, |
||||
BEVACIZUMAB, FLUOROURACIL, |
||||
| 700 | 25012245 |
HK |
||
Disease progression, Death, |
||||
ATEZOLIZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28